Travere Therapeutics (TVTX) Other financing activities (2014 - 2026)
Travere Therapeutics' (TVTX) quarterly Other financing activities came in at $4.7 million in Q1 2026, up 11.45% YoY from $4.2 million in Q1 2025, and down 81.78% on a QoQ basis from $25.9 million in Q4 2025.
Travere Therapeutics (TVTX) Other financing activities (2014 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 13 years of Other financing activities data on file, last reported at $4.7 million in Q1 2026.
- Quarterly Other financing activities rose 11.45% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.2 million (up 730.33% YoY) and the FY2025 annual result came in at $34.7 million, changed N/A from the prior year.
- Other financing activities retreated to $4.7 million in Q1 2026, from $25.9 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $25.9 million in Q4 2025 to a low of -$4.2 million in Q3 2023.
- A 5-year average of $2.7 million and a median of $1.3 million in 2024 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 4644.48% in 2025, down 307.04% in 2025.
- Tracing TVTX's Other financing activities over 5 years: stood at -$4.0 million in 2022, then surged by 207.01% to $4.3 million in 2023, then tumbled by 113.31% to -$571000.0 in 2024, then soared by 4644.48% to $25.9 million in 2025, then tumbled by 81.78% to $4.7 million in 2026.
- The last three Other financing activities figures came in at $4.7 million (Q1 2026), $25.9 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.84 Mn |
| Jun 30, 2026 | 27.84 Mn |
| Mar 31, 2026 | 4.73 Mn |
| Mar 31, 2026 | 4.73 Mn |
| Dec 31, 2025 | 25.95 Mn |
| Dec 31, 2025 | 25.95 Mn |
| Sep 30, 2025 | 7.26 Mn |
| Sep 30, 2025 | 7.26 Mn |
| Jun 30, 2025 | -2.71 Mn |
| Jun 30, 2025 | -2.71 Mn |
| Mar 31, 2025 | 4.24 Mn |
| Mar 31, 2025 | 4.24 Mn |
| Dec 31, 2024 | -571,000.00 |
| Dec 31, 2024 | -571,000.00 |
| Sep 30, 2024 | -736,000.00 |
| Sep 30, 2024 | -736,000.00 |
| Jun 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 1.31 Mn |
| Dec 31, 2023 | 4.29 Mn |
| Dec 31, 2023 | 4.29 Mn |